PCSK9 inhibitors – Page 5

Pricey Drugs Largely To Blame For Uptick In National Health Expenditures

ACA, Centers for Medicare and Medicaid Services (CMS), Health, Healthcare, Hepatitis, PCSK9 inhibitors, Pricing, Therapeutics

What do you get when you combine Obamacare with an expected explosion in the use of pricey drugs and the rapid aging of the Baby Boomer population? The answer, courtesy […]

July 28, 2015/by Forbes Health

New heart drugs come in more expensive than expected

Cholesterol, Drug Classes, Future Blockbusters, Health, Heart Failure, PCSK9 inhibitors, Pricing, Therapeutics

Two of the most anticipated new heart drugs to be launched in recent years have been priced well above analyst expectations, fuelling the debate about whether modern medicines cost too […]

July 27, 2015/by Reuters Health

Regeneron and Sanofi Announce FDA Approval of Praluent (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients

Approvals, Cholesterol, FDA/Regulatory, Health, PCSK9 inhibitors, Therapeutics

TARRYTOWN, N.Y. and PARIS, July 24, 2015 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) approved Praluent® (alirocumab) Injection, the […]

July 24, 2015/by PR Newswire

FDA approves Sanofi/Regeneron cholesterol drug with limits

Approvals, FDA/Regulatory, Future Blockbusters, Health, PCSK9 inhibitors, Therapeutics

The U.S. Food and Drug Administration approved a potent new cholesterol-lowering drug from Sanofi SA and Regeneron Pharmaceuticals Inc on Friday but limited its approved use to patients with a […]

July 24, 2015/by Reuters Health

How Many Americans Could be Treated with new PCSK9 Inhibitors? (Hint: It Won’t be as Many as Critics Claim)

Cholesterol, Health, PCSK9 inhibitors

WASHINGTON, July 24, 2015 /PRNewswire-USNewswire/ — Despite claims that tens of millions of Americans could be eligible for treatment with a new class of cholesterol-lowering medications, called PCSK9 inhibitors, the […]

July 24, 2015/by PR Newswire